多肽定制CDK5 Substrate [PK-pT-PKKAKKL], Phosphoryl 编码

发表于2024年4月18日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	CDK5 Substrate [PK-pT-PKKAKKL], Phosphoryl
编码
别名	CDK5 Substrate [PK-pT-PKKAKKL], Phosphoryl
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	PK-pT-PKKAKKL
序列（三字母缩写）	H-Pro-Lys-pThr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH (trifluoroacetate salt)
基本描述	The native peptide PKTPKKAKKL is derived from histone H1 peptide sequence that is docked in the active site of cyclin-dependent kinase 5. It is an effective CDK5 substrate (Km = 40 碌M).
溶解度
分子量	1218.5
化学式
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference	Lew, J. Biochem. 42, 849 (2003) Sharma, P. et al. J. Biol. Chem. 274, 9600 (1999)
C端
N端
化学桥

PK9327

发表于2024年4月14日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PK9327

PK9327 是一种小分子稳定剂，靶向空腔的 p53 癌症突变。

PK9327 Chemical Structure

CAS No. : 2413987-20-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	PK9327 is a small-molecule stabilizer targeting cavity-creating p53 cancer mutations.
分子量	334.48
Formula	C₂₁H₂₂N₂S
CAS 号	2413987-20-7
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Bauer MR, et al. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm. ACS Chem Biol. 2020 Mar 20;15(3):657-668.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PK11007

发表于2024年4月14日由上海金畔生物科技有限公司

PK11007 纯度: 99.0%

PK11007 是具有抗癌活性的温和硫醇烷基化剂。PK11007 通过两个表面暴露的半胱氨酸的选择性烷基化来稳定 p53，而不影响其 DNA 结合活性。PK11007 通过增加活性氧 (ROS) 水平诱导突变的 p53 癌细胞死亡。

PK11007 Chemical Structure

CAS No. : 874146-69-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥2310	In-stock
5 mg	￥2100	In-stock
10 mg	￥3300	In-stock
25 mg	￥6600	In-stock
50 mg	￥15000	In-stock
100 mg		询价

* Please select Quantity before adding items.

PK11007 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Apoptosis Compound Library
Immunology/Inflammation Compound Library
Metabolism/Protease Compound Library
NF-κB Signaling Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Autophagy Compound Library
Anti-Aging Compound Library
Antioxidants Compound Library
Oxygen Sensing Compound Library
Ferroptosis Compound Library
Pyroptosis Compound Library
Glutamine Metabolism Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Mitochondria-Targeted Compound Library
Transcription Factor Targeted Library
Anti-Colorectal Cancer Compound Library

生物活性

PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes p53 via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity. PK11007 induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels^[1]^[2].

体外研究
(In Vitro)

PK11007 (0-120 µM; 24 hours; four p53 wild-type cell lines and fours p53 mutant cell lines) treatment results in a large viability reduction in mutant p53 cell lines MKN1 (V143A), HUH-7 (Y220C), NUGC-3 (Y220C), and SW480 (R273H/P309S) at concentrations ranging from 15 to 30 µM. PK11007 induces mainly caspase-independent cell death^[1].
PK11007 (0-60 µM; 3 hours or 6 hours; NUGC-4, NUGC-3, MKN1, HUH-6, and HUH-7 cancer cells) treatment up-regulates protein levels of the p53 target genes p21, MDM2, and PUMA in a mostly concentration-dependent manner in NUGC-3 (p53-Y220C), HUH-7 (p53-Y220C) and MKN1 (p53-V143A) cells, suggesting partial restoration of transcriptional activity to destabilized p53 mutants. PK11007 also increases p53 activity in HUH-6 and NUGC-4 cells, as indicated by the increase of MDM2, PUMA, and p21 protein levels^[1].
PK11007 (15-20 µM; 4.5 hours or 6 hours; MKN1, HUH-7, NUGC-3, HUH-6 cells) treatment increases transcription of p53 target genes in three mutant p53 cell lines after 6-h treatment. PUMA and p21 mRNA levels are up-regulated by a factor of 2 upon treatment of NUGC-3, MKN, and HUH-7 cells, as well as NOXA for the latter two. MDM2 levels are halved in MKN1 and NUGC-3 cells^[1].
PK11007 viability reduction is potentiated by glutathione depletion. To test whether PK11007 also increases ROS levels, NUGC-3, NUGC-4, HUH-6, HUH-7, and MKN1 cells with PK11007 are incubated for 2 h. There are elevated ROS levels in all cell lines after 2 h. In the mutant p53 cells MKN1, HUH-7, and NUGC-3, however, the ROS increase is higher at 60 µM PK11007 than in NUGC-4 and HUH-6 cells, suggesting that the higher PK11007 sensitivity of the mutant p53 cell lines is mediated by a stronger ROS induction. Basal and PK11007-induced ROS levels in MKN1 cells are at least twofold higher than in other cell lines^[1].
PK11007 inhibits cell proliferation, induces apoptosis and alters genes involved in cell death are all consistent with the ability of PK11007 to reactivate mutant p53^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	p53 wild-type cell lines (WI-38, HUH-6, NUGC-4, SJSA-1) and p53 mutant cell lines (HUH-7, NUGC-3, SW480, MKN1)
Concentration:	0 μM, 20 μM, 40 μM, 60 µM, 80 µM, 100 µM and 120 µM
Incubation Time:	24 hours
Result:	There was a large viability reduction in mutant p53 cell lines MKN1 (V143A), HUH-7 (Y220C), NUGC-3 (Y220C), and SW480 (R273H/P309S) and in p53 WT cell line SJSA-1 at concentrations ranging from 15 to 30 µM. The p53 WT cancer cell lines HUH-6, NUGC-4 and WI-38 were less sensitive with reduced cell viability only at high concentrations of compound (60 and 120 µM).

Western Blot Analysis^[1]

Cell Line:	NUGC-4, NUGC-3, MKN1, HUH-6, and HUH-7 cancer cells
Concentration:	0 μM, 15 μM, 30 μM, 60 µM
Incubation Time:	3 hours or 6 hours
Result:	Up-regulated protein levels of the p53 target genes p21, MDM2, and PUMA in a mostly concentration-dependent manner in NUGC-3 (p53-Y220C), HUH-7 (p53-Y220C) and MKN1 (p53-V143A) cells. Also increased p53 activity in HUH-6 and NUGC-4 cells, as indicated by the increase of MDM2, PUMA, and p21 protein levels.

RT-PCR^[1]

Cell Line:	MKN1, HUH-7, NUGC-3, HUH-6 cells
Concentration:	15 μM, 20 μM
Incubation Time:	4.5 hours or 6 hours
Result:	Increased transcription of p53 target genes in three mutant p53 cell lines after 6-h treatment. PUMA and p21 mRNA levels were up-regulated by a factor of 2 upon treatment of NUGC-3, MKN, and HUH-7 cells, as well as NOXA for the latter two. MDM2 levels were halved in MKN1 and NUGC-3 cells.

分子量

427.86

Formula

C₁₅H₁₁ClFN₅O₃S₂

CAS 号

874146-69-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (584.30 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3372 mL	11.6861 mL	23.3721 mL
5 mM	0.4674 mL	2.3372 mL	4.6744 mL
10 mM	0.2337 mL	1.1686 mL	2.3372 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.86 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.86 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.86 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.86 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Bauer MR, et al. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5271-80.

[2]. Synnott NC, et al. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2018 Feb 1;414:99-106

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

上海雷磁 PK-202钾离子复合电极

发表于2024年4月1日由上海金畔生物科技有限公司

上海雷磁 PK-202钾离子复合电极

品牌雷磁|lei-ci

型号 PK-202

商品详情

离子选择性电极是电位与给定溶液中离子活度的对数呈线性关系的电化学式敏感元件，是一类利用膜电位测定溶液中离子活度或浓度的电化学传感器属于膜电极，其核心部件是电极尖端的感应膜。离子选择性电极法是电位分析的分支，一般用于直接电位法，也可用于电位滴定。其特点是：可测定溶液中特定离子的浓度；应用范围广；不受试剂颜色、浊度等的影响。

离子选择性电极的应用

离子选择性电极的分析对象很广，只要选择正确的离子测量方法、离子计和电极便可以测得相应离子的浓度值。现已成功应用于环境监测、水质监测、土壤分析、食品检测、药物分析等领域。

技术参数：

型号名称	技术参数	配套电极	电极插头
PF-202-L型氟离子复合电极	10-1～10-6	DZS-708L,PXSJ-227L	BNC（Q9型）
PF-202型氟离子复合电极	1～2×10-6	pH、离子计，不可充	BNC（Q9型）
PCl-202氯离子复合电极	1～5×10-5	pH、离子计，不可充	BNC（Q9型）
PK-202钾离子复合电极	10-1～10-6	pH、离子计，不可充	BNC（Q9型）
PCa-202钙离子复合电极	10-1～10-5	pH、离子计，不可充	BNC（Q9型）
701型钠离子复合电极	0-6pNa；溶液温度：5-45℃	钠离子计	BNC（Q9型）

测量范围：（10-1-10-5）mol/L

温度范围：5-60℃

液接界：POM单盐桥

参比结构：Ag/AgCl

敏感膜：PVC

外壳材料：有机玻璃

填充液：不可充

外形尺寸：Φ12×120mm
接插件：BNC（Q9型）

上海雷磁 PK-202钾离子复合电极

SIGMA希格玛实验室通用型离心机 2-16PK

发表于2024年2月25日由上海金畔生物科技有限公司

SIGMA希格玛实验室通用型离心机 2-16PK

商品品牌： SIGMA希格玛

商品编号：2-16PK

商品价格：请与我们联系

SIGMA希格玛实验室通用型离心机 2-16PK-SIGMA希格玛-2-16PK

主机最高转速:10001～20000rpm
品牌属性:进口

类型:高速冷冻离心机

实验室常用设备|||混合分离|||离心机|||SIGMA希格玛实验室通用型离心机2-16PK

实验室通用型离心机微型离心机高速冷冻离心机

SIGMA希格玛实验室通用型离心机 2-16PK产品简介：

1、实验室通用型离心机,可配水平转子及角转子；
2、水平转子处理量可达4*100ml,角转子可达20000*g；

3、不锈钢腔体，不平衡保护功能；
4、磁性转头识别，避免转头过速；
5、可设置11小时59分钟分钟，短时（点动）或连续运转；
6、双重盖关闭及锁紧系统；
7、缓慢制动、缓慢启动；
8、液晶显示运转时间、转速、相对离心力和温度；
9、符合国际安全标准，（如IEC1010）；

10、可显示相对离心力；

11、可存储50个程序。

商品属性

主机最高转速:10001～20000rpm
品牌属性:进口

类型:高速冷冻离心机

商品属性
商品名称	SIGMA希格玛实验室通用型离心机 2-16PK-2-16PK-SIGMA希格玛
型号	2-16PK
类别	实验室常用设备\|\|\|混合分离\|\|\|离心机\|\|\|SIGMA希格玛实验室通用型离心机2-16PK
品牌	SIGMA希格玛
品牌简介	SIGMA希格玛
关键字	实验室通用型离心机微型离心机高速冷冻离心机,离心机,转子,通用型,实验室,碳刷,离心力

SIGMA希格玛实验室通用型离心机 2-16PK

上海雷磁钾电极PK-1-01

发表于2024年1月5日由上海金畔生物科技有限公司

上海雷磁钾电极PK-1-01

品牌雷磁|lei-ci

型号 PK-1-01

商品详情

离子选择性电极的应用

技术参数：

型号	测量范围 (mol/L)	温度范围（℃）	外壳材料	外形尺寸（mm）	接插件
PF-1/PF-1-01氟离子	10-1-10-6	5-45	玻璃	Φ12×120	直插/BNC
PCl-1/ PCl-1-01氯离子	10-1-5×10-5	5-60	有机玻璃	Φ12×120	直插/BNC
PK-1/PK-1-01钾离子	10-1-10-5	5-60	有机玻璃	Φ12×120	直插/BNC
PCa-1/PCa-1-01钙离子	10-1-10-5	5-60	有机玻璃	Φ12×120	直插/BNC
PNO3-1/PNO3-1-01硝酸根离子	10-1-10-5	5-60	有机玻璃	Φ12×120	直插/BNC
PBF4-1/PBF4-1-01氟硼酸根离子	10-1-3×10-6	5-60	有机玻璃	Φ12×120	直插/BNC
P Ag-S-1/P Ag-S-1-01银硫离子	10-1-3×10-7	5-60	有机玻璃	Φ12×120	直插/BNC
PPb-1/PPb-1-01铅离子	10-1-5×10-7	5-60	有机玻璃	Φ12×120	直插/BNC
PCN-1/PCN-1-01氰离子	10-2-10-6	5-60	有机玻璃	Φ12×120	直插/BNC
PI-1/PI-1-01碘离子	10-1-5×10-7	5-60	有机玻璃	Φ12×120	直插/BNC
PCu-1/PCu-1-01铜离子	10-1-5×10-7	5-60	有机玻璃	Φ12×120	直插/BNC

多肽定制p3K truncated, [Lys58,60,63]-Ea(54-68) 编码

发表于2024年1月2日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	p3K truncated, [Lys58,60,63]-Ea(54-68)
编码
别名	p3K truncated, [Lys58,60,63]-Ea(54-68)
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	FEAKGAKANKAVD
序列（三字母缩写）	Phe-Glu-Ala-Lys-Gly-Ala-Lys-Ala-Asn-Lys-Ala-Val-Asp
基本描述
溶解度
分子量	1348.53
化学式	C59H97N17O19
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

多肽定制p3K, [Lys58,60,63]-Ea(52-68) 编码

发表于2024年1月1日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	p3K, [Lys58,60,63]-Ea(52-68)
编码
别名	p3K, [Lys58,60,63]-Ea(52-68)
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	ASFEAQKAKANKAVDKA
序列（三字母缩写）	Ala-Ser-Phe-Glu-Ala-Gln-Lys-Ala-Lys-Ala-Asn-Lys-Ala-Val-Asp-Lys-Ala
基本描述
溶解度
分子量	1777.03
化学式	C77H129N23O25
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

PKRA83(Synonyms: PKRA7)

发表于2023年12月23日由上海金畔生物科技有限公司

PKRA83 (Synonyms: PKRA7)

PKRA83 (PKRA7) 是一种有效的促动力 (PK2) 拮抗剂，可竞争 PK2 与其受体 PKR1 和 PKR2 的结合。PKRA83 有效抑制 PK2 受体，对 PKR1 和 PKR2 的 IC₅₀ 值分别为 5.0 nM 和 8.2 nM。PKRA83 具有抗癌和抗血管生成活性。 PKRA83 可以穿透血脑屏障。

PKRA83 Chemical Structure

CAS No. : 1233926-87-8

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	PKRA83 (PKRA7) is a potent prokineticin (PK2) antagonist, which can compete for the binding of PK2 to its receptors PKR1 and PKR2. PKRA83 potently inhibits PK2 receptors, with IC₅₀ values of 5.0 nM and 8.2 nM for PKR1 and PKR2, respectively. PKRA83 has anticancer and anti-angiogenic activities. PKRA83 can penetrate the blood-brain barrier^[1].
IC₅₀ & Target	IC50: 5.0 nM (PKR1) and 8.2 nM (PKR2)^[1]
体外研究 (In Vitro)	PKRA83 (PKRA7; 1 µg/mL) effectively reduces PK2-induced microvascular endothelial cell branching in vitro^[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)	PKRA83 (PKRA7; 20 mg/kg; i.p) shows anti-tumor activity in the context of glioblastoma and pancreatic cancer xenograft tumor models. For the highly vascularized glioblastoma, PKRA83 (PKRA7) is associated with decreased blood vessel density and increased necrotic areas in the tumor mass^[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	505.02
Formula	C₂₇H₃₄ClFN₂O₄
CAS 号	1233926-87-8
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Valerie F Curtis, et al. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS One. 2013;8(1):e54916.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-8

发表于2023年12月15日由上海金畔生物科技有限公司

DNA-PK-IN-8

DNA-PK-IN-8 (compound DK1) 是一种高效且具有选择性和口服活性的 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂，IC₅₀ 为 0.8 nM。DNA-PK-IN-8 与 Doxorubicin 联合使用时，对一系列癌细胞具有协同抗增殖活性，并能显著抑制 HL-60 肿瘤的生长。

DNA-PK-IN-8 Chemical Structure

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin^[1].

IC₅₀ & Target

IC₅₀: 0.8 nM (DNA-PK)^[1]

体外研究
(In Vitro)

DNA-PK-IN-8 (compound DK1) decreases the expression levels of γH2A.X in a concentration-dependent manner in HCT-116 cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence

Cell Line:	HCT-116 (treated with Bleomycin for 6 hours)^[1]
Concentration:	1, 5, and 10 μM
Incubation Time:	6 hours
Result:	Decreased the expression levels of γH2A.X in a concentration-dependent manner.

体内研究
(In Vivo)

DNA-PK-IN-8 (100 mg/kg; PO; QD for 16 days) significantly suppresses HL-60 tumor growth when co-administrating with Doxorubicin^[1].
DNA-PK-IN-8 (5 mg/kg; PO; single dosage) exhibits reasonable pharmacokinetic properties in vitro and in vivo as an oral drug candidate^[1].
Pharmacokinetic Parameters of DNA-PK-IN-8 in Sprague-Dawley rats^[1].

	PO (5 mg/kg)
T_max (h)	0.42 ± 0.11
t_1/2 (h)	1.59 ± 0.26
C_max (ng/mL)	810 ± 122.32
AUC_0-∞ (ng/mL·h)	3598.7 ± 769.81
MRT_0-∞ (h)	2.29 ± 0.18

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HL-60 tumor-bearing nude mice model^[1]
Dosage:	100 mg/kg
Administration:	PO; QD for 16 days
Result:	Led to significant tumor-suppressing effects with TGI values of 52.4% and 62.4% for tumor weight and tumor volume, respectively, when co-administrated with Doxorubicin.

Animal Model:	Sprague-Dawley rats^[1]
Dosage:	5 mg/kg
Administration:	PO; single dosage (Pharmacokinetic Analysis)
Result:	Exhibited reasonable pharmacokinetic properties in vitro and in vivo as an oral drug candidate.

分子量

394.43

Formula

C₁₉H₂₂N₈O₂

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Ding Z, et al. Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy. Eur J Med Chem. 2022;237:114401.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-9

发表于2023年12月15日由上海金畔生物科技有限公司

DNA-PK-IN-9

DNA-PK-IN-9 (compound YK6) 是一种有效的 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂，IC₅₀ 为 10.47 nM。DNA-PK-IN-9 可用于抗癌研究。

DNA-PK-IN-9 Chemical Structure

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-9 (compound YK6) is a potent DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of 10.47 nM. DNA-PK-IN-9 can be used for researching anticancer^[1].
IC₅₀ & Target	IC₅₀: 10.47 nM (DNA-PK)^[1]
分子量	375.42
Formula	C₂₁H₂₁N₅O₂
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Ding Z, et al. Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy. Eur J Med Chem. 2022;237:114401.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-7

发表于2023年12月3日由上海金畔生物科技有限公司

DNA-PK-IN-7

DNA-PK-IN-7 是一种有效的 DNA-PK 抑制剂，IC₅₀ 为 1 nM (WO2021104277A1, compound 5)。

DNA-PK-IN-7 Chemical Structure

CAS No. : 2646592-18-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-7 is a potent DNA-PK inhibitor with an IC₅₀ of 1 nM (WO2021104277A1, compound 5)^[1].
分子量	407.43
Formula	C₁₉H₂₁N₉O₂
CAS 号	2646592-18-7
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Pyrimidoimidazole compounds used as dna-pk inhibitors. WO2021104277A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-7

发表于2023年12月3日由上海金畔生物科技有限公司

DNA-PK-IN-7

DNA-PK-IN-7 是一种有效的 DNA-PK 抑制剂，IC₅₀ 为 1 nM (WO2021104277A1, compound 5)。

DNA-PK-IN-7 Chemical Structure

CAS No. : 2646592-18-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-7 is a potent DNA-PK inhibitor with an IC₅₀ of 1 nM (WO2021104277A1, compound 5)^[1].
分子量	407.43
Formula	C₁₉H₂₁N₉O₂
CAS 号	2646592-18-7
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Pyrimidoimidazole compounds used as dna-pk inhibitors. WO2021104277A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-7

发表于2023年12月3日由上海金畔生物科技有限公司

DNA-PK-IN-7

DNA-PK-IN-7 是一种有效的 DNA-PK 抑制剂，IC₅₀ 为 1 nM (WO2021104277A1, compound 5)。

DNA-PK-IN-7 Chemical Structure

CAS No. : 2646592-18-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-7 is a potent DNA-PK inhibitor with an IC₅₀ of 1 nM (WO2021104277A1, compound 5)^[1].
分子量	407.43
Formula	C₁₉H₂₁N₉O₂
CAS 号	2646592-18-7
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Pyrimidoimidazole compounds used as dna-pk inhibitors. WO2021104277A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-3

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-3

DNA-PK-IN-3 是一种有效的 DNA-PK 抑制剂。DNA-PK-IN-3 协同增强放化疗效果，有效抑制肿瘤生长。DNA-PK-IN-3 还有效减少对正常细胞的损伤，减少副作用。DNA-PK-IN-3 具有研究癌症疾病的潜力 (信息摘自专利 WO2021213460A1，化合物 4)。

DNA-PK-IN-3 Chemical Structure

CAS No. : 2734846-19-4

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4)^[1].
分子量	389.41
Formula	C₁₉H₁₉N₉O
CAS 号	2734846-19-4
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Bin Liu, et al. Tricyclic kinase inhibitors. Patent WO2021213460A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-4

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-4

DNA-PK-IN-4 是一种有效的 DNA-PK 抑制剂。DNA-PK-IN-4 是一种咪唑啉酮衍生物化合物。DNA-PK-IN-4 抑制 DNA-PKcs 活性，从而大大降低肿瘤 DNA 修复并诱导细胞进入凋亡程序。DNA-PK-IN-4 具有研究癌症疾病的潜力 (摘自专利 WO2021209055A1，化合物 27)。

DNA-PK-IN-4 Chemical Structure

CAS No. : 2722645-10-3

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-4 is a potent inhibitor of DNA-PK. DNA-PK-IN-4 is a imidazolinone derivative compound. DNA-PK-IN-4 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021209055A1, compound 27)^[1].
分子量	396.44
Formula	C₂₀H₂₄N₆O₃
CAS 号	2722645-10-3
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Yonggang Wei, et al. Imidazolinone derivatives and their applications in medicine. Patent WO2021209055A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-6

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-6

DNA-PK-IN-6 是一种有效的 DNA-PK 抑制剂。DNA-PK-IN-6 抑制 DNA-PKcs 活性，从而大大降低肿瘤 DNA 修复并诱导细胞进入凋亡程序。DNA-PK-IN-6增强肿瘤组织对放疗的敏感性，克服耐药问题，增强对多种实体瘤和血液肿瘤的抑制作用 (摘自专利 WO2021197159A1，化合物 6)^{[ 1]}。

DNA-PK-IN-6 Chemical Structure

CAS No. : 2711810-41-0

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of drug resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6)^[1].
分子量	363.42
Formula	C₁₉H₂₁N₇O
CAS 号	2711810-41-0
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Xinhai Chen, et al. Macrocyclic compounds as dna-pk inhibitors. Patent WO2021197159A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-5

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-5

DNA-PK-IN-5 是一种有效的 DNA-PK 抑制剂。DNA-PK-IN-5 抑制 DNA-PKcs 活性，从而大大降低肿瘤 DNA 修复并诱导细胞进入凋亡程序。DNA-PK-IN-5 增强肿瘤组织对放疗的敏感性，克服耐药问题，增强对多种实体瘤和血液肿瘤的抑制作用 (摘自专利 WO2021204111A1，化合物 2)^{[ 1]}。

DNA-PK-IN-5 Chemical Structure

CAS No. : 2719736-43-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of drug resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2)^[1].
分子量	418.45
Formula	C₂₁H₂₂N₈O₂
CAS 号	2719736-43-1
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Xinhai Chen, et al. Aminopyrimidine compounds and their derivatives as dna-pk inhibitors. Patent WO2021204111A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-3

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-3

DNA-PK-IN-3 Chemical Structure

CAS No. : 2734846-19-4

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4)^[1].
分子量	389.41
Formula	C₁₉H₁₉N₉O
CAS 号	2734846-19-4
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Bin Liu, et al. Tricyclic kinase inhibitors. Patent WO2021213460A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DNA-PK-IN-4

发表于2023年11月30日由上海金畔生物科技有限公司

DNA-PK-IN-4

DNA-PK-IN-4 Chemical Structure

CAS No. : 2722645-10-3

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	DNA-PK-IN-4 is a potent inhibitor of DNA-PK. DNA-PK-IN-4 is a imidazolinone derivative compound. DNA-PK-IN-4 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021209055A1, compound 27)^[1].
分子量	396.44
Formula	C₂₀H₂₄N₆O₃
CAS 号	2722645-10-3
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Yonggang Wei, et al. Imidazolinone derivatives and their applications in medicine. Patent WO2021209055A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

赛默飞Alfa aesar官网

赛默飞Acros试剂中国官网 Alfa aesar阿法埃莎中国代理商

标签归档：pk

多肽定制CDK5 Substrate [PK-pT-PKKAKKL], Phosphoryl 编码

PK9327

PK11007

PK11007 相关产品

•相关化合物库:

上海雷磁 PK-202钾离子复合电极

SIGMA希格玛实验室通用型离心机 2-16PK

SIGMA希格玛实验室通用型离心机 2-16PK

SIGMA希格玛实验室通用型离心机 2-16PK-SIGMA希格玛-2-16PK

商品属性

上海雷磁钾电极PK-1-01

多肽定制p3K truncated, [Lys58,60,63]-Ea(54-68) 编码

多肽定制p3K, [Lys58,60,63]-Ea(52-68) 编码

PKRA83(Synonyms: PKRA7)

DNA-PK-IN-8

DNA-PK-IN-9

DNA-PK-IN-7

DNA-PK-IN-7

DNA-PK-IN-7

DNA-PK-IN-3

DNA-PK-IN-4

DNA-PK-IN-6

DNA-PK-IN-5

DNA-PK-IN-3

DNA-PK-IN-4

PK11007 相关产品

•相关化合物库:

SIGMA希格玛 实验室通用型离心机 2-16PK

SIGMA希格玛 实验室通用型离心机 2-16PK-SIGMA希格玛-2-16PK

商品属性

SIGMA希格玛实验室通用型离心机 2-16PK

SIGMA希格玛实验室通用型离心机 2-16PK-SIGMA希格玛-2-16PK